Holen Sie sich die Stockscreener-App
68.72
0.59%
0.40
Handel nachbörslich:
69.00
0.28
+0.41%
Halozyme Therapeutics Inc Aktie (HALO) Neueste Nachrichten
Implied Volatility Surging for Halozyme Therapeutics Stock Options - TradingView
Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a Promising 22.8% Potential Upside - DirectorsTalk Interviews
(HALO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Flat Share Price And Strong Longer Term Returns - Sahm
Halozyme Therapeutics Q1 earnings call highlights - MSN
HALO News | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme posts strong Q1 earnings, boosts share buyback with $1B program amid robust royalty growth - Pluang
Halozyme Therapeutics: Royalty King (NASDAQ:HALO) - Seeking Alpha
New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO) - simplywall.st
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
HALO Stock Price, Quote & Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Alteogen Gains Momentum in Patent Defense for Merck's Subcutaneous Keytruda - thelec.net
Halozyme Therapeutics (HALO) Stock Analysis: A 27.3% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - MSN
Halozyme Therapeutics Experiences Valuation Adjustment Amid Competitive Biotechnology Landscape - Markets Mojo
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Halozyme Therapeutics Q1 2026 Earnings Review | HALO StockNews and Statistics - IndexBox
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO) - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook - Yahoo Finance
Morgan Stanley Smith Barney files Form 144 (NASDAQ: HALO) to sell 14,700 shares - Stock Titan
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback - Sahm
Arbejdsmarkedets Tillaegspension Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback - MSN
Halozyme appoints Darren Snellgrove as CFO - MSN
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75 - Moomoo
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative - Sahm
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares - MarketBeat
Halozyme CEO Helen Torley sells $3.43m in stock By Investing.com - Investing.com Nigeria
Halozyme CEO Helen Torley sells $3.43m in stock - Investing.com
Halozyme (HALO) CEO Torley exercises 50K options and sells 50K shares under 10b5-1 plan - Stock Titan
(HALO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Halozyme Therapeutics Earnings: What To Look For From HALO - Yahoo Finance
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK - Insider Monkey
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41 - Moomoo
HALO Stock Jumps After Earnings Beat And $1B Buyback - StocksToTrade
Halozyme jumps as Q1 results, $1B buyback authorization, and new partnership updates lift sentiment - Quiver Quantitative
Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00 - MarketBeat
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley - marketscreener.com
Halozyme Therapeutics Shares Jumping 8.1% on Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and … - AlphaStreet
Halozyme Therapeutics (NASDAQ:HALO) Trading Up 6.6% Following Strong Earnings - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript - Insider Monkey
Citizens reiterates Halozyme stock rating on strong Q1 results By Investing.com - Investing.com Nigeria
Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating - marketscreener.com
Citizens reiterates Halozyme stock rating on strong Q1 results - Investing.com
Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlight - GuruFocus
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96 - Moomoo
Halozyme Therapeutics (HALO) Reports Strong Q1 2026 Earnings and Growth Outlook - GuruFocus
Halozyme Therapeutics Q1 Earnings Call Highlights - Inkl
Halozyme Q1 2026 slides: revenue surges 42%, $1B buyback unveiled - Investing.com Canada
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):